SEC Tracker
Get the app

Equillium EQ

Equillium Q4 FY25: net loss $5.3M; diluted EPS −$0.06

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Equillium reported for Q4 FY25, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$5.3MAgainst −$8.7M in Q1 FY2510-Q income statement, on EDGAR
  2. Diluted EPS−$0.06Against −$0.24 in Q1 FY2510-Q income statement, on EDGAR
  3. Cash and cash equivalents$61.3M+323% from $14.5M in Q1 FY2510-Q balance sheet, on EDGAR
  4. Cash from operations−$4.3MAgainst −$8.2M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Equillium files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zeo ScientifiX ZEOX public float $7M, Apr 30, 2025, over 18 months old
  2. Sunshine Biopharma SBFM public float $7M, Jun 30, 2025
  3. Neuphoria Therapeutics NEUP public float $7M, Dec 31, 2025
  4. CV Sciences CVSI public float $7M, Jun 30, 2025
  5. Minerva Neurosciences NERV public float $7M, Jun 30, 2025